The Fraser Institute

The Fraser Institute

November 06, 2013 08:15 ET

The Fraser Institute: Media Advisory; How Do Delays in Approving New Cancer Medicines Affect Patients? New Study Coming Thursday, November 7

TORONTO, ONTARIO--(Marketwired - Nov. 6, 2013) - The Fraser Institute will release a new study Thursday November 7 examining how delays in approving five new oncology drugs affected Canadian patients.

The study, Potential Patients Impacted by Delayed Access to Five Oncology Drugs in Canada by Nigel Rawson, PhD., looks at:

  • Aspects of cancer and the five drugs: Avastin, Halaven, Jevtana, Tarceva and Torisel which treat solid tumours that have spread to other parts of the body;

  • Benefits, risks and regulatory and reimbursement milestones; and

  • Estimates of the potential numbers of patients impacted by delayed access and the potential economic value of lives lost.

A news release with additional information will be issued via Marketwired at 6:30 a.m. (Eastern) on Thursday, November 7.

The full report will also be available as a free PDF download at www.fraserinstitute.org.

Follow the Fraser Institute on Twitter and Facebook

The Fraser Institute is an independent Canadian public policy research and educational organization with offices in Vancouver, Calgary, Toronto, and Montreal and ties to a global network of 86 think-tanks. Its mission is to measure, study, and communicate the impact of competitive markets and government intervention on the welfare of individuals. To protect the Institute's independence, it does not accept grants from governments or contracts for research. Visit www.fraserinstitute.org.

Contact Information